Diagnostic Products Corporation Receives FDA Clearance to Market IMMULITE Third Generation PSA Assay.LOS ANGELES--(BW HealthWire)--Nov. 13, 1997-- Highly Sensitive Test Provides Improvement In The Management of Prostate Cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. Diagnostic Products Corporation (NYSE NYSE See: New York Stock Exchange :DP) today announced that it has received FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. clearance for marketing of its IMMULITE Third Generation PSA (Professional Services Automation) An information system designed to organize, track and manage all opportunities, work, resources, costs, revenues and invoices to improve the productivity and efficiency of the workforce. assay, a new ultrasensitive method to aid in the management of prostate cancer patients. The company will begin shipments of the assay immediately to hospitals and clinical laboratories. The prostate-specific-antigen (PSA) is widely recognized as the most specific tumor marker generally available and a key indicator for the evaluation of prostate cancer. Diagnostic Products' IMMULITE Third Generation PSA assay has the lowest analytical detection limit and functional sensitivity commercially available. The assay is offered for use with Diagnostic Products' IMMULITE immunoassay Immunoassay An assay that quantifies antigen or antibody by immunochemical means. The antigen can be a relatively simple substance such as a drug, or a complex one such as a protein or a virus. analyzer, an automated random access system. "Diagnostic Products' Third Generation PSA Assay is the most sensitive assay to date to be put on the market," said Thomas A. Stamey, M.D., and Professor of Urology at Stanford Medical Center. "The assay's ultrasensitivity is a tremendous advantage in monitoring cancer patients, allowing clinicians an important time advantage in which to assess and treat patients. Also, the results gained through this assay can be reassuring to patients, who are understandably concerned whether their cancer has been successfully treated." "This approval marks a significant addition to the urologists' armamentarium ar·ma·men·tar·i·um n. pl. ar·ma·men·tar·i·ums or ar·ma·men·tar·i·a The complete equipment of a physician or medical institution, including drugs, books, supplies, and instruments. ," said Michael Ziering, president of Diagnostic Products Corporation. "With estimates showing that one in five American men will develop prostate cancer in their lifetime, the ultrasensitive Third Generation PSA Assay will provide clinicians with important immunodiagnostic immunodiagnostic pertaining to diagnosis by immune reactions. information during the monitoring of their cancer patients. The new assay provides a solid growth opportunity for Diagnostic Products in the fast-growing urology market and further expands the company's IMMULITE product line." Founded in 1971, Diagnostic Products Corporation (DPC DPC Department of Premier and Cabinet (Victoria, Australia) DPC Dutch Power Cows DPC Deferred Procedure Calls (Microsoft Windows NT 4. ) develops, produces, and supports a wide variety of immunodiagnostic products for clinical and research laboratories. It is one of the world's fastest growing in vitro diagnostic manufacturers for automated immunoassay systems and reagents, and is the worldwide leader in fertility assays. With over 300 tests, DPC's products are used by hospitals, as well as clinical, forensic, research and veterinary laboratories domestically and in more than 100 foreign countries. CONTACT: Diagnostic Products Corporation Michael Ziering, 213/776-0180 or Morgen-Walke Associates John Swenson/Micah Epps/Doug Sherk, 415/296-7383 (Investor Relations) Sheryl Seapy, Carol Lehrman, 415/296-7383 (Media Relations) Sandra Badurina/Joshua Passman, 212/850-5600 (Wire Services) |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion